Selected Projects

• Determined the price elasticity of demand (PED) for Gleevec among CML patients using separate regression discontinuity designs assessing the impact of Medicare Part D enrollment at age 65 on adherence and OOP.

• Estimated the dynamic effect of non-adherence and non-initiation to Gleevec on time to remission in CML patients via marginal structural Cox model.

Collaborated with researchers at the Institute for Disease Modeling (IDM) to implement a dynamic HIV transmission model and led initial development of the corresponding cost-effectiveness analysis.

Assisted in the development and implementation of a dynamic decision-making framework integrating prediction modeling, machine learning, and econometric value of information analysis to optimize cancer recurrence surveillance using EHR data within a patient-level microsimulation.

Characterized longitudinal patterns of adherence to TKIs in chronic myeloid leukemia patients via latent profile analysis. Predictors of membership in these categories were determined using multinomial logistic regression.

Assessed the value of a data integration intelligence platform’s ability to expedite the drug development process by navigating the large space of possible therapies and prioritizing synergistic treatment combinations for glioblastoma multiforme.

Developed quantitative models assessing the economic benefits, broader social and economic value, and return on investment associated with vaccine introduction and scale-up in 94 low- and middle-income countries in collaboration with UNICEF, WHO, and Gavi, the Vaccine Alliance.

Built epidemiologic and economic models to estimate the economic burden of vaccine-preventable diseases associated with fourteen unique pathogens among U.S. adults

Undertook return on investment analyses for selected mental health innovations globally, including epidemiological and economic modeling of population health trajectories, scale-up costs, and economic benefits as a consultant for the World Health Organization.